Artificial intelligence has entered this landscape not as a gimmick but as a genuinely transformative capability. The biological complexity of cancer — the thousands of mutations, gene expression patterns, protein interactions, and immune signals that distinguish one patient's tumor from another's — exceeds the capacity of any unaided human clinician to fully integrate.
AI systems trained on vast datasets of genomic, transcriptomic, and clinical data can identify patterns invisible to conventional analysis, predict drug responses, stratify patients by risk, and match individuals to therapies or trials with a precision that would have been inconceivable a generation ago.
AI has become the essential tool for navigating that complexity. Machine learning models trained on curated genomic databases — including The Cancer Genome Atlas, which contains molecular profiles for more than thirty tumor types — can now analyze a patient's tumor genome and identify clinically significant mutations with speed and accuracy that far exceed manual review.
Variant calling algorithms distinguish true somatic mutations from sequencing artifacts. Pathway analysis tools map mutations to biological networks, identifying which cellular processes have been disrupted and which therapeutic targets may be vulnerable. Deep learning models trained on both genomic and clinical outcome data can stratify patients by predicted survival, treatment response, and recurrence risk.
"synopsis" may belong to another edition of this title.
Seller: PBShop.store US, Wood Dale, IL, U.S.A.
PAP. Condition: New. New Book. Shipped from UK. THIS BOOK IS PRINTED ON DEMAND. Established seller since 2000. Seller Inventory # L0-9798255256723
Seller: PBShop.store UK, Fairford, GLOS, United Kingdom
PAP. Condition: New. New Book. Delivered from our UK warehouse in 4 to 14 business days. THIS BOOK IS PRINTED ON DEMAND. Established seller since 2000. Seller Inventory # L0-9798255256723
Quantity: Over 20 available
Seller: CitiRetail, Stevenage, United Kingdom
Paperback. Condition: new. Paperback. Artificial intelligence has entered this landscape not as a gimmick but as a genuinely transformative capability. The biological complexity of cancer - the thousands of mutations, gene expression patterns, protein interactions, and immune signals that distinguish one patient's tumor from another's - exceeds the capacity of any unaided human clinician to fully integrate. AI systems trained on vast datasets of genomic, transcriptomic, and clinical data can identify patterns invisible to conventional analysis, predict drug responses, stratify patients by risk, and match individuals to therapies or trials with a precision that would have been inconceivable a generation ago. AI has become the essential tool for navigating that complexity. Machine learning models trained on curated genomic databases - including The Cancer Genome Atlas, which contains molecular profiles for more than thirty tumor types - can now analyze a patient's tumor genome and identify clinically significant mutations with speed and accuracy that far exceed manual review. Variant calling algorithms distinguish true somatic mutations from sequencing artifacts. Pathway analysis tools map mutations to biological networks, identifying which cellular processes have been disrupted and which therapeutic targets may be vulnerable. Deep learning models trained on both genomic and clinical outcome data can stratify patients by predicted survival, treatment response, and recurrence risk. This item is printed on demand. Shipping may be from our UK warehouse or from our Australian or US warehouses, depending on stock availability. Seller Inventory # 9798255256723
Quantity: 1 available
Seller: AHA-BUCH GmbH, Einbeck, Germany
Taschenbuch. Condition: Neu. Neuware. Seller Inventory # 9798255256723